JP7224067B2 - フマル酸ジメチルを含有する腸溶性錠剤 - Google Patents

フマル酸ジメチルを含有する腸溶性錠剤 Download PDF

Info

Publication number
JP7224067B2
JP7224067B2 JP2021557880A JP2021557880A JP7224067B2 JP 7224067 B2 JP7224067 B2 JP 7224067B2 JP 2021557880 A JP2021557880 A JP 2021557880A JP 2021557880 A JP2021557880 A JP 2021557880A JP 7224067 B2 JP7224067 B2 JP 7224067B2
Authority
JP
Japan
Prior art keywords
enteric
fibrosis
core
weight
coated tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519933A (ja
Inventor
キム，ミョンファ
ピョ，ジョンイン
モ，ジョンヒョン
リ，チョルウ
ジ，ヒョング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curacle Co Ltd
Original Assignee
Curacle Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curacle Co Ltd filed Critical Curacle Co Ltd
Publication of JP2022519933A publication Critical patent/JP2022519933A/ja
Priority to JP2022177059A priority Critical patent/JP2023026417A/ja
Application granted granted Critical
Publication of JP7224067B2 publication Critical patent/JP7224067B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021557880A 2019-05-31 2020-05-21 フマル酸ジメチルを含有する腸溶性錠剤 Active JP7224067B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022177059A JP2023026417A (ja) 2019-05-31 2022-11-04 フマル酸ジメチルを含有する腸溶性錠剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190064576 2019-05-31
KR10-2019-0064576 2019-05-31
PCT/KR2020/006647 WO2020242132A1 (ko) 2019-05-31 2020-05-21 디메틸푸마르산염을 함유한 장용성 정제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022177059A Division JP2023026417A (ja) 2019-05-31 2022-11-04 フマル酸ジメチルを含有する腸溶性錠剤

Publications (2)

Publication Number Publication Date
JP2022519933A JP2022519933A (ja) 2022-03-25
JP7224067B2 true JP7224067B2 (ja) 2023-02-17

Family

ID=73553277

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557880A Active JP7224067B2 (ja) 2019-05-31 2020-05-21 フマル酸ジメチルを含有する腸溶性錠剤
JP2022177059A Pending JP2023026417A (ja) 2019-05-31 2022-11-04 フマル酸ジメチルを含有する腸溶性錠剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022177059A Pending JP2023026417A (ja) 2019-05-31 2022-11-04 フマル酸ジメチルを含有する腸溶性錠剤

Country Status (10)

Country Link
US (2) US20220087942A1 (US20020128544A1-20020912-P00008.png)
EP (1) EP3977986A4 (US20020128544A1-20020912-P00008.png)
JP (2) JP7224067B2 (US20020128544A1-20020912-P00008.png)
KR (1) KR102197465B1 (US20020128544A1-20020912-P00008.png)
CN (1) CN113645962A (US20020128544A1-20020912-P00008.png)
AU (1) AU2020283238B2 (US20020128544A1-20020912-P00008.png)
BR (1) BR112021018452B1 (US20020128544A1-20020912-P00008.png)
CA (1) CA3135946C (US20020128544A1-20020912-P00008.png)
MX (1) MX2021012441A (US20020128544A1-20020912-P00008.png)
WO (1) WO2020242132A1 (US20020128544A1-20020912-P00008.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021012441A (es) * 2019-05-31 2022-10-07 Curacle Co Ltd Tableta enterica que contiene fumarato de dimetilo.
WO2022203432A1 (ko) * 2021-03-25 2022-09-29 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
KR20240069303A (ko) * 2022-11-11 2024-05-20 주식회사 대웅제약 방출 제어형 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104288774A (zh) 2014-04-21 2015-01-21 河南省健康伟业生物医药研究股份有限公司 一种肠溶包衣、富马酸二甲酯肠溶制剂及其制备方法
US20150246016A1 (en) 2014-02-28 2015-09-03 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
KR20090028047A (ko) 2007-09-13 2009-03-18 경북대학교 산학협력단 디메틸푸마레이트의 신규 용도
KR20100066742A (ko) * 2008-12-10 2010-06-18 삼일제약주식회사 안정화된 프로톤 펌프 억제제 함유 약학 조성물
EP2379062A1 (en) * 2009-01-09 2011-10-26 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
EP3466420A1 (en) 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
KR101379427B1 (ko) 2013-02-13 2014-03-28 경북대학교병원 디메틸푸마레이트를 유효성분으로 포함하는 신섬유증의 예방 또는 치료용 조성물
US20160206587A1 (en) * 2013-08-26 2016-07-21 Forward Pharma A/S Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
KR102335289B1 (ko) * 2013-12-12 2021-12-06 알미랄, 에스.에이. 디메틸 푸마레이트를 포함하는 약학적 조성물
CN104352441B (zh) * 2014-10-16 2017-06-09 山东百诺医药股份有限公司 一种富马酸二甲酯肠溶微丸及其制备方法
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
KR102283582B1 (ko) * 2014-12-23 2021-07-30 한미약품 주식회사 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
MX2017009849A (es) * 2015-02-08 2017-12-11 Alkermes Pharma Ireland Ltd Composiciones de profármaco de monometilfumarato.
WO2016147108A1 (en) * 2015-03-17 2016-09-22 Hetero Research Foundation Pharmaceutical compositions of dimethyl fumarate
US10085961B2 (en) * 2015-06-01 2018-10-02 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN104971048B (zh) * 2015-07-01 2019-01-18 上海汇伦医药科技有限公司 富马酸二甲酯肠溶微丸及其制备方法
WO2017056107A1 (en) * 2015-09-28 2017-04-06 Natco Pharma Ltd Pharmaceutical compositions of dimethyl fumarate
RS62813B1 (sr) * 2015-12-31 2022-02-28 Zakl Farmaceutyczne Polpharma Sa Enterično obložen oralni farmaceutski preparat koji sadrži dimetil fumarat
GR1009149B (el) * 2016-10-25 2017-10-31 Φαρματεν Αβεε Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων
MX2021012441A (es) * 2019-05-31 2022-10-07 Curacle Co Ltd Tableta enterica que contiene fumarato de dimetilo.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246016A1 (en) 2014-02-28 2015-09-03 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
CN104288774A (zh) 2014-04-21 2015-01-21 河南省健康伟业生物医药研究股份有限公司 一种肠溶包衣、富马酸二甲酯肠溶制剂及其制备方法

Also Published As

Publication number Publication date
BR112021018452A2 (US20020128544A1-20020912-P00008.png) 2021-12-21
KR102197465B1 (ko) 2020-12-31
US20240180841A1 (en) 2024-06-06
BR112021018452B1 (pt) 2022-10-04
JP2022519933A (ja) 2022-03-25
MX2021012441A (es) 2022-10-07
CA3135946A1 (en) 2020-12-03
AU2020283238A1 (en) 2022-01-06
KR20200138005A (ko) 2020-12-09
EP3977986A4 (en) 2022-07-20
CA3135946C (en) 2022-08-09
US20220087942A1 (en) 2022-03-24
EP3977986A1 (en) 2022-04-06
JP2023026417A (ja) 2023-02-24
WO2020242132A1 (ko) 2020-12-03
CN113645962A (zh) 2021-11-12
AU2020283238B2 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
AU2019268049B2 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
KR101699912B1 (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
JP7224067B2 (ja) フマル酸ジメチルを含有する腸溶性錠剤
WO2005092336A1 (ja) 溶出制御製剤とその製造方法
EP3437646A1 (en) Oral preparation having exceptional elutability
AU2017215530B2 (en) Galenic formulations of organic compounds
JP5479909B2 (ja) 新規製剤
TW201442712A (zh) 有機化合物之調配物
EP3437645B1 (en) Film-coated tablet having high chemical stability of active ingredient
US20110274752A1 (en) Modified release pharmaceutical compositions of dexlansoprazole
KR102104507B1 (ko) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
RU2786364C1 (ru) Энтеросолюбильная таблетка, содержащая диметилфумарат
JP2023537647A (ja) オービットアジンフマル酸塩腸溶性ペレット、その調製方法及び使用
WO2021106004A1 (en) Pharmaceutical composition of s-adenosylmethionine
JP6673798B2 (ja) カペシタビンを有効成分とするフィルムコート医薬製剤
JP7195354B2 (ja) 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤
JP6707471B2 (ja) ピロールカルボキサミドの固形組成物
JP2022042886A (ja) アビラテロン酢酸エステル含有製剤
MX2013010661A (es) Preparacion solida.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210928

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221115

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221227

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230131

R150 Certificate of patent or registration of utility model

Ref document number: 7224067

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150